This site provides INTERCEPT product information for International audiences Select your region
![broad_routine_use_2022.png broad_routine_use_2022.png](https://interceptbloodsystem.com/sites/default/files/styles/interc_paragraph_66/public/content/broad_routine_use_2022.png?itok=S2COoDq-)
Safety in routine use has been demonstrated through several haemovigilance programmes evaluating >300,000 platelet transfusions.
- French National Haemovigilance programme - ANSM
- Swiss National Haemovigilance programme - Swissmedic
- Cerus Multicenter Haemovigilance programme
Safety in routine use has also been demonstrated in different patient populations such as cardiovascular patients, haematology/oncology patients, and neonatal and paediatric patients.
When transfusing INTERCEPT-treated platelet concentrates, you know that safety and efficacy have been validated in routine conditions in first-rate haemovigilance programmes.